VOR BIOPHARMA INC (VOR) Stock Fundamental Analysis

NASDAQ:VOR • US9290332074

14.33 USD
+0.78 (+5.76%)
Last: Feb 23, 2026, 09:42 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

1

VOR gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 521 industry peers in the Biotechnology industry. VOR has a bad profitability rating. Also its financial health evaluation is rather negative. VOR has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year VOR has reported negative net income.
  • VOR had a negative operating cash flow in the past year.
  • VOR had negative earnings in each of the past 5 years.
  • VOR had a negative operating cash flow in each of the past 5 years.
VOR Yearly Net Income VS EBIT VS OCF VS FCFVOR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -1389.92%, VOR is doing worse than 95.20% of the companies in the same industry.
Industry RankSector Rank
ROA -1389.92%
ROE N/A
ROIC N/A
ROA(3y)-57.36%
ROA(5y)-53.18%
ROE(3y)-78.63%
ROE(5y)-74.06%
ROIC(3y)N/A
ROIC(5y)N/A
VOR Yearly ROA, ROE, ROICVOR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

1.3 Margins

  • VOR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VOR Yearly Profit, Operating, Gross MarginsVOR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • The number of shares outstanding for VOR has been increased compared to 1 year ago.
  • Compared to 5 years ago, VOR has more shares outstanding
  • There is no outstanding debt for VOR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
VOR Yearly Shares OutstandingVOR Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
VOR Yearly Total Debt VS Total AssetsVOR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • Based on the Altman-Z score of -28.53, we must say that VOR is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -28.53, VOR is not doing good in the industry: 86.37% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -28.53
ROIC/WACCN/A
WACCN/A
VOR Yearly LT Debt VS Equity VS FCFVOR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

  • VOR has a Current Ratio of 9.16. This indicates that VOR is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 9.16, VOR is in the better half of the industry, outperforming 79.27% of the companies in the same industry.
  • A Quick Ratio of 9.16 indicates that VOR has no problem at all paying its short term obligations.
  • VOR has a Quick ratio of 9.16. This is in the better half of the industry: VOR outperforms 79.27% of its industry peers.
Industry RankSector Rank
Current Ratio 9.16
Quick Ratio 9.16
VOR Yearly Current Assets VS Current LiabilitesVOR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • The earnings per share for VOR have decreased strongly by -85.24% in the last year.
EPS 1Y (TTM)-85.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.38%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 14.21% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-278.79%
EPS Next 2Y35.57%
EPS Next 3Y22.56%
EPS Next 5Y14.21%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VOR Yearly Revenue VS EstimatesVOR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 2033 500M 1B
VOR Yearly EPS VS EstimatesVOR Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -100 -200

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for VOR. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VOR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VOR Price Earnings VS Forward Price EarningsVOR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VOR Per share dataVOR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -20 -40 -60

4.3 Compensation for Growth

  • A more expensive valuation may be justified as VOR's earnings are expected to grow with 22.56% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.57%
EPS Next 3Y22.56%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • VOR does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

VOR BIOPHARMA INC

NASDAQ:VOR (2/23/2026, 9:42:55 AM)

14.33

+0.78 (+5.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)03-18
Inst Owners37.49%
Inst Owner Change566.5%
Ins Owners0.01%
Ins Owner Change-167.03%
Market Cap594.98M
Revenue(TTM)N/A
Net Income(TTM)-2.45B
Analysts83.64
Price Target39.44 (175.23%)
Short Float %6.71%
Short Ratio1.26
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-197.99%
Min EPS beat(2)-394.6%
Max EPS beat(2)-1.38%
EPS beat(4)0
Avg EPS beat(4)-115.27%
Min EPS beat(4)-394.6%
Max EPS beat(4)-1.38%
EPS beat(8)3
Avg EPS beat(8)-56.4%
EPS beat(12)4
Avg EPS beat(12)-37.86%
EPS beat(16)6
Avg EPS beat(16)-27.88%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)6.23%
PT rev (3m)-2.73%
EPS NQ rev (1m)0%
EPS NQ rev (3m)19.2%
EPS NY rev (1m)0%
EPS NY rev (3m)-131.16%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-61.13
EYN/A
EPS(NY)-5.51
Fwd EYN/A
FCF(TTM)-3.48
FCFYN/A
OCF(TTM)-3.47
OCFYN/A
SpS0
BVpS-53.6
TBVpS-53.6
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -1389.92%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-57.36%
ROA(5y)-53.18%
ROE(3y)-78.63%
ROE(5y)-74.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 18.75%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.16
Quick Ratio 9.16
Altman-Z -28.53
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)123.83%
Cap/Depr(5y)265.1%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-85.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.38%
EPS Next Y-278.79%
EPS Next 2Y35.57%
EPS Next 3Y22.56%
EPS Next 5Y14.21%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-211.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-207.98%
EBIT Next 3Y-22.64%
EBIT Next 5YN/A
FCF growth 1Y-50.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-52.18%
OCF growth 3YN/A
OCF growth 5YN/A

VOR BIOPHARMA INC / VOR FAQ

What is the fundamental rating for VOR stock?

ChartMill assigns a fundamental rating of 1 / 10 to VOR.


What is the valuation status for VOR stock?

ChartMill assigns a valuation rating of 1 / 10 to VOR BIOPHARMA INC (VOR). This can be considered as Overvalued.


How profitable is VOR BIOPHARMA INC (VOR) stock?

VOR BIOPHARMA INC (VOR) has a profitability rating of 0 / 10.


What is the financial health of VOR BIOPHARMA INC (VOR) stock?

The financial health rating of VOR BIOPHARMA INC (VOR) is 3 / 10.


What is the earnings growth outlook for VOR BIOPHARMA INC?

The Earnings per Share (EPS) of VOR BIOPHARMA INC (VOR) is expected to decline by -278.79% in the next year.